{"id":"W4388487685","doi":"10.1158/1078-0432.ccr-23-2249","title":"Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Clinical endpoint; Cohort; Bevacizumab; Internal medicine; Oncology; Durvalumab; PARP inhibitor; Adverse effect; Cancer; Clinical trial; Chemotherapy; Nivolumab; Poly ADP ribose polymerase; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002693644,0.00116976,0.001373427,0.0003346242,0.0004187296,0.001069601,0.0008105743,0.0006971711,0.001544743],"category_scores_gemma":[0.001594642,0.0005237393,0.001599705,0.0004023715,0.0006992395,0.0008093613,0.0004371194,0.002026873,0.000397101],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009873008,"about_ca_system_score_gemma":0.001536921,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001042559,"about_ca_topic_score_gemma":0.002346733,"domain_scores_codex":[0.9990548,0.0004889428,0.00005115174,0.0002002832,0.000112371,0.00009244416],"domain_scores_gemma":[0.9987745,0.0001913225,0.0002887718,0.0002278318,0.00006953358,0.0004481415],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7613295,0.07004414,0.06237838,0.0004930937,0.005566805,0.0003368253,0.000353359,0.00188424,0.02487587,0.0001892275,0.002113367,0.07043512],"study_design_scores_gemma":[0.4786452,0.394855,0.1086721,0.00006093469,0.003793316,0.0009693331,0.000210076,0.003397972,0.00534688,0.0002982522,0.003667494,0.00008355404],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979196,0.0007392771,0.0001853357,0.00009429802,0.00002808213,0.0003861312,0.0003893878,0.00001496597,0.0002429362],"genre_scores_gemma":[0.9966936,0.0006761911,0.0006170615,0.0002269146,0.00007485049,0.0004022121,0.000920011,0.000009414548,0.0003797469],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002693644,"threshold_uncertainty_score":0.01424551,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.317749283599929,"score_gpt":0.5762641648363642,"score_spread":0.2585148812364352,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}